Nystatin

Pruritus Vulvae, Trichomonas Vaginitis, Pruritus Ani + 13 more

Treatment

15 Active Studies for Nystatin

What is Nystatin

Nystatin

The Generic name of this drug

Treatment Summary

Nystatin is a medication used to treat fungal infections caused by yeasts and certain fungi, such as Candida species. It is derived from a type of bacteria called Streptomyces noursei and is very similar to the drug amphotericin B. Nystatin is generally more effective than amphotericin B, but it has more side effects when given intravenously. It is not absorbed into the bloodstream when taken orally or applied topically, making it only suitable for treating infections on the skin, mucous membranes, and digestive tract.

Nystatin

is the brand name

image of different drug pills on a surface

Nystatin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nystatin

Nystatin

1979

252

Effectiveness

How Nystatin Affects Patients

Nystatin is an antifungal that fights and kills yeast and similar fungi. It works by breaking down the walls of the fungal cells. This drug is usually effective against _Candida albicans_, but sometimes resistance can develop in other species of _Candida_. Nystatin does not work against bacteria, protozoa, or viruses. It can cause serious side effects if taken in large doses, so it is only used to treat topical, oral, and gastrointestinal infections.

How Nystatin works in the body

Nystatin is a drug that works by creating tiny holes in the cell walls of fungi. This makes it easier for the cell's contents to leak out, which disrupts the electrical and chemical balance needed for the cell to work properly. Nystatin only affects fungi, not mammals, because it has a stronger bond with the fungus's sterol (a type of fat) than with cholesterol, which is found in mammal cells.

When to interrupt dosage

The prescribed dose of Nystatin is contingent upon the diagnosed condition, including cutaneous candidiasis, Skin candida and corticosteroid-responsive dermatoses. The amount of dosage varies as per the technique of delivery (e.g. Insert or Insert - Vaginal) featured in the table beneath.

Condition

Dosage

Administration

Skin candida

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Anal candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Skin Diseases

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Oral

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Low; Birthweight

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Ani

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

cutaneous candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Urinary Tract Infection (UTI)

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candida albicans

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Vulvae

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Trichomonas Vaginitis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Invasive

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Yeast Infection

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Warnings

Nystatin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nystatin may interact with Pulse Frequency

There are 20 known major drug interactions with Nystatin.

Common Nystatin Drug Interactions

Drug Name

Risk Level

Description

Revefenacin

Major

Nystatin may decrease the excretion rate of Revefenacin which could result in a higher serum level.

Ambrisentan

Minor

The excretion of Ambrisentan can be decreased when combined with Nystatin.

Asunaprevir

Minor

The excretion of Asunaprevir can be decreased when combined with Nystatin.

Atorvastatin

Minor

The excretion of Atorvastatin can be decreased when combined with Nystatin.

Atrasentan

Minor

The excretion of Atrasentan can be decreased when combined with Nystatin.

Nystatin Toxicity & Overdose Risk

Nystatin has been found to be toxic in rats at a dose of 10g/kg. Taking too much nystatin may lead to nausea and stomach discomfort, but no other serious side effects have been reported, even with doses over 5 million units per day.

image of a doctor in a lab doing drug, clinical research

Nystatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Nystatin?

39 active trials are in progress to assess the effectiveness of Nystatin in treating Urinary Tract Infection (UTI), Candidal Infection and Pruritus Ani.

Condition

Clinical Trials

Trial Phases

Pruritus Ani

0 Actively Recruiting

Candida albicans

0 Actively Recruiting

Skin candida

0 Actively Recruiting

Anal candidiasis

0 Actively Recruiting

Candidiasis, Invasive

4 Actively Recruiting

Phase 3, Not Applicable

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Candidiasis, Oral

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Low; Birthweight

2 Actively Recruiting

Not Applicable

Skin Diseases

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Candidiasis

0 Actively Recruiting

Candidiasis, Vulvovaginal

2 Actively Recruiting

Not Applicable, Phase 3

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Pruritus Vulvae

0 Actively Recruiting

Candidiasis, Vulvovaginal

0 Actively Recruiting

Nystatin Reviews: What are patients saying about Nystatin?

5

Patient Review

9/2/2019

Nystatin for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

I developed oral thrush after a week of the antibiotic metronidazole. I’m on day 4 of nystatin and my thrush is getting worse instead of better. My lips are now chapping and my entire mouth has a burnt feeling. My tastebuds aren’t the same and the taste in my mouth from the nystatin is terrible.

5

Patient Review

12/22/2018

Nystatin for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

5

Patient Review

3/31/2022

Nystatin for Stomach and Intestinal Infection caused by the Fungus Candida

Nystatin 5mil really helped me with my oral fungus. I saw results within just a few days, and it was completely gone after a week. This stuff is magic!

4.3

Patient Review

4/27/2022

Nystatin for Thrush

I was prescribed this medication for thrush, which is a side effect of my asthma medication. I take 1ml every four hours and have found that it tastes great! It's also been really effective in healing my mouth.

4.3

Patient Review

2/2/2021

Nystatin for Thrush

I occasionally get thrush from my corticosteroid asthma inhalers. This time it was bad and felt like it was spreading to my throat. I've been using the treatment for 3 days now, and the feeling is gone from my throat, and my tongue/mouth are healing. When you get thrush, it feels like your tongue is burnt.

4

Patient Review

10/26/2020

Nystatin for Thrush

I was given this medication by my doctor after an antibiotic I took for surgery caused a thrush outbreak in my mouth. The results were noticeable very quickly, with the pain and white patches disappearing within days. However, as I had to swallow the medication, it did cause some stomach upset and diarrhea.

4

Patient Review

10/16/2021

Nystatin for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

I know a lot of people say this tastes terrible, but I personally didn't mind it.

3

Patient Review

3/26/2022

Nystatin for Thrush

I developed ulcers on my tongue while using this treatment for 10 days, which caused me a great deal of pain. I also had to take Tums for the abdominal pains and diarrhea. Overall, not a great experience.

3

Patient Review

12/18/2021

Nystatin for Thrush

I'm not sure how I got oral thrush, but Nystatin was the worst experience of my life. I was on it for 10 days and my mouth and tongue were swollen for weeks afterwards. I had anxiety the whole time because I didn't know if the Nystatin would ever wear off.

2.3

Patient Review

8/26/2020

Nystatin for Stomach and Intestinal Infection caused by the Fungus Candida

I've been taking this medication for four months now, four tablets a day as directed, and I haven't seen any improvement in my symptoms. Bloating and gas are still a major problem for me.

2

Patient Review

5/28/2021

Nystatin for Thrush

I've only taken the medication twice so I can't speak to its effectiveness yet. However, the taste is absolutely terrible. It's so bad that I have to brush my teeth aggressively after taking it. I can't stand to hold it in my mouth for more than 90 seconds. It's just incredibly foul tasting.

1

Patient Review

5/5/2020

Nystatin for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

I have diabetes and developed thrush in my throat. After just two days of using this treatment, I went into anaphylactic shock and had to go to the emergency room. It was a severe allergic reaction.

1

Patient Review

5/7/2020

Nystatin for Stomach and Intestinal Infection caused by the Fungus Candida

The taste of this medication is incredibly off-putting, to the point where I feel nauseous 24 hours a day. I have used it as directed three times now and seen zero improvement in my condition. Will be asking doctor for a different prescription.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nystatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Should I swallow nystatin or spit it out?

"Nystatin pastilles should be held in the mouth and allowed to dissolve slowly and completely, which may take 15-30 minutes. The saliva should be swallowed during this time. Do not chew or swallow the lozenges whole."

Answered by AI

Does nystatin have side effects?

"If you experience mouth irritation, diarrhea, nausea, vomiting, or stomach upset, notify your doctor or pharmacist. Remember that your doctor has prescribed this medication because they believe the benefits outweigh the risks of side effects."

Answered by AI

Why was nystatin discontinued?

"The Nystan brand of nystatin pastilles has been discontinued for commercial reasons, and recent stock shortages have made it difficult to find supplies of the product."

Answered by AI

What is nystatin used to treat?

"Nystatin is an antifungal drug used to either treat or prevent fungal infections caused by yeast."

Answered by AI

Clinical Trials for Nystatin

Have you considered Nystatin clinical trials?

We made a collection of clinical trials featuring Nystatin, we think they might fit your search criteria.
Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

Phase 4
Recruiting

Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)

Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Phase 4
Recruiting

University of Missouri

Kevin M Klifto, DO, PharmD

Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Antifungal Therapy Duration for Candidemia in Children

120 - 18
All Sexes
Philadelphia, PA

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

Recruiting
Has No Placebo

Children's Hospital of Philadelphia (+17 Sites)

Brian Fisher, DO

Have you considered Nystatin clinical trials?

We made a collection of clinical trials featuring Nystatin, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Data Accountability + Doula Support for Maternal Health Disparities

12 - 99
Female
Chapel Hill, NC

This project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 39 prenatal practices across North Carolina. Practices have been randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for \~750-1,500 patients (up to 60,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.

Recruiting
Has No Placebo

University of North Carolina at Chapel Hill

Jennifer H Tang, MD, MSCR

Image of Houston Methodist Hospital - Texas Medical Center in Houston, United States.

Fosmanogepix for Candida Blood Infection

18+
All Sexes
Houston, TX

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

Phase 3
Recruiting

Houston Methodist Hospital - Texas Medical Center (+12 Sites)

Manuel Häckl, MD

Basilea Pharmaceutica

Have you considered Nystatin clinical trials?

We made a collection of clinical trials featuring Nystatin, we think they might fit your search criteria.
Go to Trials